{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:34:25Z","timestamp":1784630065436,"version":"3.55.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Die Kerndokumentation der Regionalen Kooperativen Rheumazentren erfasst j\u00e4hrlich Versorgungsdaten von Patient:innen mit entz\u00fcndlich rheumatischen Erkrankungen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodik<\/jats:title>\n                    <jats:p>F\u00fcr rheumatoide Arthritis (RA), Psoriasisarthritis (PsA), axiale Spondyloarthritis (axSpA), systemischen Lupus erythematodes (SLE), systemische Sklerose (SSc), Sj\u00f6gren-Syndrom (SjS), idiopathische inflammatorische Myositiden (IIM), Polymyalgia rheumatica (PMR), Riesenzellerarteriitis (RZA), ANCA-assoziierte Vaskulitiden (AAV), Morbus Beh\u00e7et (BD), \u201eadult-onset Still\u2019s disease\u201c (AOSD) und autoinflammatorische Erkrankungen (AIE) werden Daten aus dem Jahr 2023 berichtet. Angaben umfassen u.\u202fa. die \u00e4rztlich eingesch\u00e4tzte Krankheitsaktivit\u00e4t auf einer numerischen Ratingskala (NRS) von 0\u201310, Therapien und patientenberichtete Outcomes. F\u00fcr ausgew\u00e4hlte Diagnosen werden Entwicklungen von 2010 bis 2023 zu der \u00e4rztlichen Einsch\u00e4tzung der Krankheitsaktivit\u00e4t und zu Therapien dargestellt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Aus 14\u00a0Einrichtungen wurden 13.884 Patient:innen dokumentiert, am h\u00e4ufigsten RA (5734), PsA (1741) und axSpA (1494). Das mittlere Alter lag zwischen 45\u00a0(BD) und 73\u00a0Jahren (RZA), die Krankheitsdauer betrug im Median 3 (PMR) bis 16\u00a0Jahre (axSpA). Die Krankheitsaktivit\u00e4t war \u00fcberwiegend niedrig, bei 6\u202f% (BD) bis 15\u202f% (axSpA) stuften die Rheumatolog:innen sie moderat bis hoch (&gt;\u202f4 auf numerischer Ratingskala) ein. Biologische (b)DMARDs wurden am h\u00e4ufigsten bei axSpA (65\u202f%), AOSD (58\u202f%), PsA (53\u202f%) und RZA (41\u202f%) verordnet. H\u00e4ufig waren Tumornekrosefaktor(TNF)-Inhibitoren bei axSpA (53\u202f%), BD (30\u202f%) und PsA (28\u202f%), Interleukin(IL)-1-Inhibitoren bei AOSD (51\u202f%) und AIE (50\u202f%), IL-6Ri bei RZA (38\u202f%), IL-17i bei PsA (17\u202f%) und Rituximab bei AAV (29\u202f%). H\u00f6here Einschr\u00e4nkungen hinsichtlich Schmerz, Fatigue, Schlafst\u00f6rungen und Wohlbefinden dokumentierten v.\u00a0a. Betroffene mit IIM, SSc, axSpA und AIE. Von den unter 65-J\u00e4hrigen waren 58\u202f% (SSc) bis 77\u202f% (axSpA) erwerbst\u00e4tig. Eine Berentung wegen der rheumatischen Erkrankung hatten 5\u202f% (AOSD) bis 18\u202f% (AAV). In der Entwicklung seit 2010 ist der Anteil an Patienten in Remission oder sehr niedriger Krankheitsaktivit\u00e4t (NRS\u00a00\u20131) diagnose\u00fcbergreifend gestiegen. Bei den Therapien sind ein Anstieg an b\/tsDMARDs und ein R\u00fcckgang von Glukokortikoiden bei verschiedenen Diagnosen sichtbar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Die Ergebnisse zeigen die Vielf\u00e4ltigkeit der entz\u00fcndlich rheumatischen Diagnosen und das kontinuierlich wachsende Therapiespektrum in der Rheumatologie, einhergehend mit einer guten Krankheitskontrolle bei vielen Patient:innen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00393-025-01646-8","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:19:30Z","timestamp":1746418770000},"page":"761-771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Jahresbericht 2025 aus der Kerndokumentation der Regionalen Kooperativen Rheumazentren","Annual report 2025 from the National Database of the Regional Collaborative Rheumatology Centers in Germany"],"prefix":"10.1007","volume":"84","author":[{"given":"Katinka","family":"Albrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Detert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Eidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Feuchtenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Karberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta G.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Sp\u00e4thling-Mestekemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Steinm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Zinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Callhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"issue":"8","key":"1646_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00393-019-0660-5","volume":"78","author":"K Albrecht","year":"2019","unstructured":"Albrecht\u00a0K, Callhoff\u00a0J, Zink\u00a0A (2019) Langzeittrends in der rheumatologischen Versorgung : Erfolge und Defizite im Spiegel von 25\u00a0Jahren rheumatologischer Kerndokumentation. (Long-term trends in rheumatology care : Achievements and deficits in 25\u00a0years of the German national rheumatology database). Z\u00a0Rheumatol 78(8):703\u2013712. https:\/\/doi.org\/10.1007\/s00393-019-0660-5","journal-title":"Z Rheumatol"},{"key":"1646_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002342","author":"K Thiele","year":"2022","unstructured":"Thiele\u00a0K, Albrecht\u00a0K, Zink\u00a0A, Aringer\u00a0M, Karberg\u00a0K, Spathling-Mestekemper\u00a0S, von Hinuber\u00a0U, Callhoff\u00a0J (2022) Is the Rheumatoid Arthritis Impact of Disease (RAID) score a\u00a0meaningful instrument for other inflammatory rheumatic diseases? A\u00a0cross-sectional analysis of data from the German National Database. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002342","journal-title":"RMD Open"},{"key":"1646_CR3","doi-asserted-by":"publisher","unstructured":"Thiele\u00a0K, Albrecht\u00a0K, Alexander\u00a0T, Aringer\u00a0M, Detert\u00a0J, Eidner\u00a0T, Feuchtenberger\u00a0M, Henes\u00a0J, Karberg\u00a0K, Kiltz\u00a0U, K\u00f6hler\u00a0B, Krause\u00a0A, Richter\u00a0JG, Sp\u00e4thling-Mestekemper\u00a0S, Steinm\u00fcller\u00a0M, Zinke\u00a0S, Callhoff\u00a0J (2025) Kerndokumentation der regionalen kooperativen Rheumazentren. Versorgungstrends 2025. https:\/\/doi.org\/10.17169\/refubium-46216","DOI":"10.17169\/refubium-46216"},{"key":"1646_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004980","author":"C Veltri","year":"2025","unstructured":"Veltri\u00a0C, Albrecht\u00a0K, Kiltz\u00a0U, Meyer-Olson\u00a0D, Spathling\u00a0S, Strangfeld\u00a0A, Thiele\u00a0K, Callhoff\u00a0J (2025) Trends in work participation among patients with inflammatory rheumatic musculoskeletal diseases (iRMDs): Data from the German National Database (2010\u20132022). Rmd Open. https:\/\/doi.org\/10.1136\/rmdopen-2024-004980","journal-title":"Rmd Open"},{"issue":"11","key":"1646_CR5","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s00296-018-4161-7","volume":"38","author":"A Steffen","year":"2018","unstructured":"Steffen\u00a0A, Holstiege\u00a0J, Klimke\u00a0K, Akmatov\u00a0MK, Batzing\u00a0J (2018) Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a\u00a0German perspective based on nationwide ambulatory drug prescription data. Rheumatol Int 38(11):2111\u20132120. https:\/\/doi.org\/10.1007\/s00296-018-4161-7","journal-title":"Rheumatol Int"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01646-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01646-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01646-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:06:18Z","timestamp":1762869978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01646-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":5,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01646-8","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"13 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Callhoff erhielt Referentenhonorare von Janssen, Pfizer und Idorsia. Tobias Alexander erhielt in den letzten 3\u00a0Jahren Honorare f\u00fcr Advisory Boards und\/oder Vortr\u00e4ge von AbbVie, Amgen, AstraZeneca, GSK und Lilly. Martin Aringer erhielt Honorare f\u00fcr Advisory Boards und\/oder Vortr\u00e4ge von AbbVie, AstraZeneca, BMS, Chugai, Galapagos, GSK, Lilly, MSD, Novartis, Roche, Sanofi und UCB. J.\u00a0Detert erhielt Advisory Board- und Vortragshonorare von AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer und UCB. Martin Feuchtenberger erhielt Honorare f\u00fcr Advisory Boards und\/oder Vortr\u00e4ge von AbbVie, Lilly, MSD, Novartis, Pfizer, Celltrion und UCB. J.\u00a0Henes erhielt Vortragshonorare f\u00fcr AbbVie, AstraZeneca, Boehringer Ingelheim, BMS, Janssen, Lilly, Novartis, Pfizer, Roche, SOBI, Otsuka, EUSA und UCB. K.\u00a0Karberg erhielt Vortragshonorare von AbbVie, UCB, Novartis und der Rheumaakademie. U.\u00a0Kiltz erhielt Vortrags\u2011\/Beratungshonorare von AbbVie, Amgen, Biocad, Biogen, Chugai, Eli Lilly, Fresenius, Gilead, Gr\u00fcnenthal, GSK, Janssen, MSD, Novartis, Pfizer, Roche und UCB. B.\u00a0K\u00f6hler erhielt Vortragshonorare von AbbVie, Lilly und Novartis, Beratungshonorare von AbbVie, Amgen, Lilly, Pfizer, UCB und Unterst\u00fctzung f\u00fcr Kongressreisen\/-teilnahme von UCB, Pfizer, Lilly und AbbVie. Susanna Sp\u00e4thling-Mestekemper erhielt Vortrags\u2011\/Beraterhonorare von AbbVie, AstraZeneca, BMS, Gilead, Gr\u00fcnenthal, GSK, Janssen, Lilly, MSD, Novartis, Pfizer, UCB. M.\u00a0Steinm\u00fcller erhielt Vortrags\u2011\/Beratungshonorare von AbbVie, Amgen, Berlin Chemie, BMS, Galapagos, Gilead, GSK, Janssen, Lilly, Medac, MSD, Mylan, Novartis, Pfizer und ViiV. A.\u00a0Strangfeld erhielt Referentenhonorare von AbbVie, Biogen, Galapagos, Janssen, Lilly, Pfizer und Takeda. K.\u00a0Albrecht, T.\u00a0Eidner, A.\u00a0Krause, J.\u00a0Richter und K.\u00a0Thiele geben an, dass bzgl. der Kerndokumentation keine Interessenkonflikte bestehen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr die Studie liegt ein positives Ethikvotum von der Charit\u00e9-Universit\u00e4tsmedizin Berlin vor (EA1\/196\/06 und EA1\/093\/24). Alle Patient:innen haben bei Teilnahme an der Kerndokumentation ihr schriftliches Einverst\u00e4ndnis gegeben.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}